HR 7537 · 116th Congress · Taxation

Infectious Disease Therapies Research and Innovation Act of 2020

Introduced 2020-07-09· Sponsored by Rep. Kelly, Mike [R-PA-16]· House

Bill Progress

Introduced
2
Committee
3
House Vote
4
Senate
5
Enacted
Latest: Referred to the House Committee on Ways and Means.(2020-07-09)

Plain Language Summary

[AI summary unavailable — showing source text] Infectious Disease Therapies Research and Innovation Act of 2020 This bill exempts from the definition of passive activity , for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity. The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.…

Summarized by Claude AI · Non-partisan · For informational purposes only